Tumour immunity: effector response to tumour and role of the microenvironment

The Lancet

Volumn 371, Issue 9614, 2008, Pages 771-783

  Mantovani, Alberto ^a   Romero, Pedro ^b   Palucka, A Karolina ^c   Marincola, Francesco M ^d  

^a UNIVERSITY OF MILAN   (Italy)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^c BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CELL ANTIGEN; CYTOKINE;

ACTIVE IMMUNIZATION; ADAPTIVE IMMUNITY; B LYMPHOCYTE; CANCER INCIDENCE; CANCER SURVIVAL; CELL ACTIVATION; CELL DESTRUCTION; CELL STIMULATION; CHRONIC INFLAMMATION; DENDRITIC CELL; DISEASE ASSOCIATION; GRAFT REJECTION; HEPATITIS B; HEPATITIS C; HUMAN; MICROENVIRONMENT; NEOPLASM; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR LOCALIZATION;

EID: 39649098678     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60241-X     Document Type: Review

References (179)

1. van der Bruggen P., Traversari C., Chomez P., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254 (1991) 1643-1647
2. Old L., and Chen Y. New paths in human cancer serology. J Exp Med 187 (1998) 1163-1167
3. Ganss R., and Hanahan D. Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes. Cancer Res 58 (1998) 4673-4681
4. Marincola F., Wang E., Herlyn M., Seliger B., and Ferrone S. Tumors as elusive targets of T cell-based active immunotherapy. Trends Immunol 24 (2003) 335-342
5. Malmberg K. Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape?. Cancer Immunol Immunother 53 (2004) 879-892
6. Overwijk W. Breaking tolerance in cancer immunotherapy: time to ACT. Curr Opin Immunol 17 (2005) 187-194
7. Perry V. The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease. Brain Behav Immun 18 (2004) 407-413
8. Eksteen B., Walker L., and Adams D. Immune regulation and colitis: suppression of acute inflammation allows the development of chronic inflammatory bowel disease. Gut 54 (2005) 4-6
9. Wouters E. Local and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2 (2005) 26-33
10. Bowen D., and Walker C. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436 (2005) 946-952
11. Crowe S. Helicobacter infection, chronic inflammation, and the development of malignancy. Curr Opin Gastroenterol 21 (2005) 32-38
12. Coussens L., Tinkle C., Hanahan D., and Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103 (2000) 481-490
13. Bergers G., Brekken R., McMahon G., et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2 (2000) 737-744
14. Panelli M., Wang E., Phan G., et al. Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol 3 (2002) RESEARCH0035.
15. Coussens L., and Werb Z. Inflammation and cancer. Nature 420 (2002) 860-867
16. Sarwal M., Chua M., Kambham N., et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 349 (2003) 125-138
17. Balkwill F., and Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 357 (2001) 539-545
18. Lokich J. Spontaneous regression of metastatic renal cancer: case report and literature review. Am J Clin Oncol 20 (1997) 416-418
19. Printz C. Spontaneous regression of melanoma may offer insight into cancer immunology. J Natl Cancer Inst 93 (2001) 1047-1048
20. Chang W. Complete spontaneous regression of cancer: four case reports, review of literature, and discussion of possible mechanisms involved. Hawaii Med J 59 (2000) 379-387
21. Hanahan D., Lanzavecchia A., and Mihich E. Fourteenth Annual Pezcoller Symposium: the novel dichotomy of immune interactions with tumors. Cancer Res 63 (2003) 3005-3008
22. Mantovani A. Cancer: inflammation by remote control. Nature 435 (2005) 752-753
23. De Visser K., Korets L., and Coussens L. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7 (2005) 411-423
24. Wolfel T., Klehmann E., Muller C., Schutt K., Meyer zum Buschenfelde K., and Knuth A. Lysis of human melanoma cells by autologous cytolytic T cell clones: identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med 170 (1989) 797-810
25. Marincola F., Rivoltini L., Salgaller M., Player M., and Rosenberg S. Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence for in vivo priming by tumor cells. J Immunother 19 (1996) 266-277
26. Shankaran V., Ikeda H., Bruce A., et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410 (2001) 1107-1111
27. Andres A. Cancer incidence after immunosuppressive treatment following kidney transplantation. Crit Rev Oncol Hematol 56 (2005) 71-85
28. Ippoliti G., Rinaldi M., Pellegrini C., and Vigano M. Incidence of cancer after immunosuppressive treatment for heart transplantation. Crit Rev Oncol Hematol 56 (2005) 101-113
29. Vallejo G., Romero C., and de Vicente J. Incidence and risk factors for cancer after liver transplantation. Crit Rev Oncol Hematol 56 (2005) 87-99
30. Ghelani D., Saliba R., and Lima M. Secondary malignancies after hematopoietic stem cell transplantation. Crit Rev Oncol Hematol 56 (2005) 115-126
31. Taylor A., Marcus R., and Bradley J. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol 56 (2005) 155-167
32. Dunn G., Old L., and Schreiber R. The three Es of cancer immunoediting. Annu Rev Immunol 22 (2004) 329-360
33. Balkwill F., Charles K., and Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7 (2005) 211-217
34. Karin M., and Greten F. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5 (2005) 749-759
35. Slingluff Jr. C., and Speiser D. Progress and controversies in developing cancer vaccines. J Transl Med 3 (2005) 18
36. Atkins M., Lotze M., Dutcher J., et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17 (1998) 2105-2116
37. Atkins M., Regan M., and McDermott D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res 10 (2004) 6342S-6346S
38. Dudley M., Wunderlich J., Robbins P., et al. Cancer regression and autoimmunity in patients after clonal repopulation wiht antitumor lymphocytes. Science 298 (2002) 850-854
39. Grillo-Lopez A., White C., Varns C., et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 26 5 suppl 14 (1999) 66-73
40. Hortobagyi G. Trastuzumab in the treatment of breast cancer. N Engl J Med 353 (2005) 1734-1736
41. Mager D., Haffajee A., Devlin P., Norris C., Posner M., and Goodson J. The salivary microbiota as a diagnostic indicator of oral cancer: a descriptive, non-randomized study of cancer-free and oral squamous cell carcinoma subjects. J Transl Med 3 (2005) 27
42. Mager D. Bacteria and cancer: cause, coincidence or cure? A review. J Transl Med 4 (2006) 14
43. Mantovani A., Sozzani S., Locati M., Allavena P., and Sica A. Macrophage polarization: tumor-associated macrophage as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23 (2002) 549-555
44. Dave S., Wright G., Tan B., et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351 (2004) 2159-2169
45. Voronov E., Shouval D., Krelin Y., et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 100 (2003) 2645-2650
46. Koehne C., and Dubois R. COX-2 inhibition and colorectal cancer. Semin Oncol 31 2 suppl 7 (2004) 12-21
47. Pikarsky E., Porat R., Stein I., et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431 (2004) 461-466
48. Wyckoff J., Wang W., Lin E., et al. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res 64 (2004) 7022-7029
49. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 3 (2003) 23-35
50. Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., and Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25 (2004) 677-686
51. Mantovani A., Sica A., and Locati M. Macrophage polarization comes of age. Immunity 23 (2005) 344-346
52. Dinarello C. Blocking IL-1 in systemic inflammation. J Exp Med 201 (2005) 1355-1359
53. Noel W., Raes G., Hassanzadeh G., De Baetselier P., and Beschin A. Alternatively activated macrophages during parasite infections. Trends Parasitol 20 (2004) 126-133
54. Wynn T. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 4 (2004) 583-594
55. Schioppa T., Uranchimeg B., Saccani A., et al. Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 198 (2003) 1391-1402
56. De Palma M., Venneri M., Galli R., et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8 (2005) 211-226
57. Biswas S., Gangi L., Paul S., et al. A distinct and unique transcriptional programme expressed by tumor-associated macrophages: defective NF-{kappa}B and enhanced IRF-3/STAT1 activation. Blood 107 (2006) 2112-2122
58. Bronte V., and Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 5 (2005) 641-654
59. Palucka K., Taquet N., Sanchez-Chapuis F., and Gluckman J. Dendritic cells as the terminal stage of monocyte differentiation. J Immunol 160 (1998) 4587-4595
60. Chomarat P., Banchereau J., Davoust J., and Palucka A. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol 1 (2000) 510-514
61. Chomarat P., Dantin C., Bennett L., Banchereau J., and Palucka A. TNF skews monocyte differentiation from macrophages to dendritic cells. J Immunol 171 (2003) 2262-2269
62. Mosser D. The many faces of macrophage activation. J Leukoc Biol 73 (2003) 209-212
63. Albini A., Tosetti F., Benelli R., and Noonan D. Tumor inflammatory angiogenesis and its chemoprevention. Cancer Res 65 (2005) 10637-10641
64. Nakao S., Kuwano T., Tsutsumi-Miyahara C., et al. Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1beta-induced neovascularization and tumor growth. J Clin Invest 115 (2005) 2979-2991
65. Rauh M., Ho V., Pereira C., et al. SHIP represses the generation of alternatively activated macrophages. Immunity 23 (2005) 361-374
66. Greten F., Eckmann L., Greten T., et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118 (2004) 285-296
67. Sparmann A., and Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6 (2004) 447-458
68. Borrello M., Alberti L., Fischer A., et al. Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci USA 102 (2005) 14825-14830
69. Colombo M., and Mantovani A. Targeting myelomonocytic cells to revert inflammation-dependent cancer promotion. Cancer Res 65 (2005) 9113-9116
70. Perri S., Nalbantoglu J., Annabi B., et al. Plasminogen kringle 5-engineered glioma cells block migration of tumor-associated macrophages and suppress tumor vascularization and progression. Cancer Res 65 (2005) 8359-8365
71. Giraudo E., Inoue M., and Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114 (2004) 623-633
72. Banchereau J., and Steinman R. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
73. Shortman K., and Liu Y. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2 (2002) 151-161
74. Liu Y. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 23 (2005) 275-306
75. Finkelman F., Lees A., Birnbaum R., Gause W., and Morris S. Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion. J Immunol 157 (1996) 1406-1414
76. Trombetta E., and Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol 23 (2005) 975-1028
77. Amsen D., Blander J., Lee G., Tanigaki K., Honjo T., and Flavell R. Instruction of distinct CD4 T helper cell fates by different notch ligands on antigen-presenting cells. Cell 117 (2004) 515-526
78. Kapsenberg M. Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol 3 12 (2003) 984-993
79. Cella M., Nakajima H., Facchetti F., Hoffmann T., and Colonna M. ILT receptors at the interface between lymphoid and myeloid cells. Curr Top Microbiol Immunol 251 (2000) 161-166
80. Yamazaki S., Iyoda T., Tarbell K., et al. Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med 198 (2003) 235-247
81. Watanabe N., Wang Y., Lee H., et al. Hassall's corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus. Nature 436 (2005) 1181-1185
82. Steinman R., Hawiger D., and Nussenzweig M. Tolerogenic dendritic cells. Annu Rev Immunol 21 (2003) 685-711
83. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 4 (2004) 941-952
84. Bell D., Chomarat P., Broyles D., et al. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med 190 (1999) 1417-1426
85. Thomas R., MacDonald K., Pettit A., Cavanagh L., Padmanabha J., and Zehntner S. Dendritic cells and the pathogenesis of rheumatoid arthritis. J Leukoc Biol 66 (1999) 286-292
86. Blanco P., Palucka A., Gill M., Pascual V., and Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 294 (2001) 1540-1543
87. Vakkila J., and Lotze M. Inflammation and necrosis promote tumour growth. Nat Rev Immunol 4 (2004) 641-648
88. Wang T., Niu G., Kortylewski M., et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10 (2004) 48-54
89. Gabrilovich D., Chen H., Girgis K., et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2 (1996) 1096-1103
90. Roncarolo M., Levings M., and Traversari C. Differentiation of T regulatory cells by immature dendritic cells. J Exp Med 193 (2001) F5-F9
91. Cambi A., and Figdor C. Levels of complexity in pathogen recognition by C-type lectins. Curr Opin Immunol 17 (2005) 345-351
92. Aarnoudse C., Vallejo J., Saeland E., and van Kooyk Y. Recognition of tumor glycans by antigen-presenting cells. Curr Opin Immunol 18 (2006) 105-111
93. Vlad A., Kettel J., Alajez N., Carlos C., and Finn O. MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 82 (2004) 249-293
94. Shortman K., and Villadangos J. Is it a DC, is it an NK? No, it's an IKDC. Nat Med 12 (2006) 167-168
95. Taieb J., Chaput N., Menard C., et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 12 (2006) 214-219
96. Chan C., Crafton E., Fan H., et al. Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med 12 (2006) 207-213
97. Pardoll D., and Allison J. Cancer immunotherapy: breaking the barriers to harvest the crop. Nat Med 10 (2004) 887-892
98. Berzofsky J., Ahlers J., Janik J., et al. Progress on new vaccine strategies against chronic viral infections. J Clin Invest 114 (2004) 450-462
99. Davis I., Jefford M., Parente P., and Cebon J. Rational approaches to human cancer immunotherapy. J Leukoc Biol 73 (2003) 3-29
100. Banchereau J., and Palucka A. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5 (2005) 296-306
101. Hsu F., Benike C., Fagnoni F., et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2 (1996) 52-58
102. Fong L., Hou Y., Rivas A., et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA 98 (2001) 8809-8814
103. Banchereau J., Palucka A., Dhodapkar M., et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61 (2001) 6451-6458
104. Schuler G., Schuler-Thurner B., and Steinman R. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 15 (2003) 138-147
105. Albert M., Sauter B., and Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392 (1998) 86-89
106. Heath W., and Carbone F. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 19 (2001) 47-64
107. Morse M., Coleman R., Akabani G., Niehaus N., Coleman D., and Lyerly H. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 59 (1999) 56-58
108. Martin-Fontecha A., Sebastiani S., Hopken U., et al. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med 198 (2003) 615-621
109. Mailliard R., Wankowicz-Kalinska A., Cai Q., et al. Alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 64 (2004) 5934-5937
110. Mullins D., Sheasley S., Ream R., Bullock T., Fu Y., and Engelhard V. Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J Exp Med 198 (2003) 1023-1034
111. Altman J., Moss P., Goulder P., et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274 (1996) 94-96
112. Bakker A., and Schumacher T. MHC multimer technology: current status and future prospects. Curr Opin Immunol 17 (2005) 428-433
113. Pittet M., Valmori D., Dunbar P., et al. High frequencies of naive MLANA/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 190 (1999) 705-715
114. Zippelius A., Pittet M., Batard P., et al. Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J Exp Med 195 (2002) 485-494
115. Dutoit V., Rubio-Godoy V., Pittet M., et al. Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/MLANA peptide multimer(+) CD8(+) T cells in humans. J Exp Med 196 (2002) 207-216
116. Osanto S., Schiphorst P., Weijl N., et al. Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line. Hum Gene Ther 11 (2000) 739-750
117. Germeau C., Ma W., Schiavetti F., et al. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 201 (2005) 241-248
118. Keilholz U., Weber J., Finke J., et al. Immunologic monitoring of cancer vaccine therapy: results of a Workshop sponsored by the Society of Biological Therapy. J Immunother 25 (2002) 97-138
119. Speiser D., Pittet M., Guillaume P., et al. Ex vivo analysis of human antigen-specific CD8+ T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-gamma ELISPOT assays for patient immune monitoring. J Immunother 27 (2004) 298-308
120. Comin-Anduix B., Gualberto A., Glaspy J., et al. Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays. Clin Cancer Res 12 (2006) 107-116
121. Lee P., Yee C., Savage P., et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5 (1999) 677-685
122. Walter S., Bioley G., Buhring H., et al. High frequencies of functionally impaired cytokeratin 18-specific CD8+ T cells in healthy HLA-A2+ donors. Eur J Immunol 35 (2005) 2876-2885
123. Valmori D., Scheibenbogen C., Dutoit V., et al. Circulating tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolitc activity. Cancer Res 62 (2002) 1743-1750
124. Meidenbauer N., Zippelius A., Pittet M., et al. High frequency of functionally active MLANA-specific T cells in a patient with progressive immunoproteasome-deficient melanoma. Cancer Res 64 (2004) 6319-6326
125. Valmori D., Pittet M., Vonarbourg C., et al. Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368-376. Cancer Res 59 (1999) 4050-4055
126. Valmori D., Dutoit V., Lienard D., et al. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res 60 (2000) 4499-4506
127. Valmori D., Dutoit V., Rubio-Godoy V., et al. Frequent cytolytic T-cell responses to peptide MAGE-A10(254-262) in melanoma. Cancer Res 61 (2001) 509-512
128. Monsurro' V., Wang E., Yamano Y., et al. Quiescent phenotype of tumor-specific CD8+ T cells following immunization. Blood 104 (2004) 1970-1978
129. Romero P., Dunbar P., Valmori D., et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 188 (1998) 1641-1650
130. Romero P., Valmori D., Pittet M., et al. Antigenicity and immunogenicity of MLANA/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev 188 (2002) 81-96
131. Benlalam H., Labarriere N., Linard B., et al. Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy. Eur J Immunol 31 (2001) 2007-2015
132. Seiter S., Monsurro V., Nielsen M., et al. Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes. J Immunother 25 (2002) 252-263
133. Gillmore R., Xue S., Holler A., et al. Detection of Wilms' tumor antigen: specific CTL in tumor-draining lymph nodes of patients with early breast cancer. Clin Cancer Res 12 (2006) 34-42
134. Broderick L., Brooks S., Takita H., Baer A., Bernstein J., and Bankert R. IL-12 reverses anergy to T cell receptor triggering in human lung tumor-associated memory T cells. Clin Immunol 118 (2006) 159-169
135. Harlin H., Kuna T., Peterson A., Meng Y., and Gajewski T. Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol Immunother 55 (2006) 1185-1197
136. Albers A., Ferris R., Kim G., Chikamatsu K., Deleo A., and Whiteside T. Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites. Cancer Immunol Immunother 54 (2005) 1072-1081
137. Mortarini R., Piris A., Maurichi A., et al. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res 63 (2003) 2535-2545
138. Zippelius A., Batard P., Rubio-Godoy V., et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res 64 (2004) 2865-2873
139. Whiteside T. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 16 (2006) 3-15
140. Dudley M., Wunderlich J., Yang J., et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23 (2005) 2346-2357
141. Wherry E., Blattman J., Murali-Krishna K., van der Most R., and Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 77 (2003) 4911-4927
142. Appay V., and Rowland-Jones S. Lessons from the study of T-cell differentiation in persistent human virus infection. Semin Immunol 16 (2004) 205-212
143. Barber D., Wherry E., Masopust D., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439 (2006) 682-687
144. Dong H., Strome S., Salomao D., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8 (2002) 793-800
145. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5 (2005) 263-274
146. Uyttenhove C., Pilotte L., Theate I., et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9 (2003) 1269-1274
147. Zea A., Rodriguez P., Atkins M., et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 65 (2005) 3044-3048
148. Woo E., Yeh H., Chu C., et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 168 (2002) 4272-4276
149. Curiel T., Coukos G., Zou L., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10 9 (2004) 942-949
150. Badoual C., Hans S., Rodriguez J., et al. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 12 (2006) 465-472
151. Badoual C., Hans S., Rodriguez J., et al. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 12 (2006) 465-472
152. Viguier M., Lemaitre F., Verola O., et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173 (2004) 1444-1453
153. Yamaguchi T., and Sakaguchi S. Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol (2005)
154. Ghiringhelli F., Puig P., Roux S., et al. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med 202 (2005) 919-929
155. Dannull J., Su Z., Rizzieri D., et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115 (2005) 3623-3633
156. Hirano F., Kaneko K., Tamura H., et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 65 (2005) 1089-1096
157. Geng H., Zhang G., Xiao H., et al. HSP70 vaccine in combination with gene therapy with plasmid DNA encoding sPD-1 overcomes immune resistance and suppresses the progression of pulmonary metastatic melanoma. Int J Cancer 118 (2006) 2657-2664
158. Haas A., Sun J., Vachani A., et al. Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine. Clin Cancer Res 12 (2006) 214-222
159. Rehermann B., and Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5 (2005) 215-229
160. Hardin J. Dendritic cells: potential triggers of autoimmunity and targets for therapy. Ann Rheum Dis 64 suppl 4 (2005) iv86-iv90
161. Matzinger P. Danger model of immunity. Scand J Immunol 54 (2001) 2-3
162. Fuchs E., and Matzinger P. Is cancer dangerous to the immune system?. Semin Immunol 8 (1996) 271-280
163. Kaech S., Hemby S., Kersh E., and Ahmed R. Molecular and functional profiling of memory CD8 T cell differentiation. Cell 111 (2002) 837-851
164. Ochsenbein A., Klenerman P., Karrer U., et al. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci USA 96 (1999) 2233-2238
165. Smith M., Yue Z., Korth M., et al. Hepatitis C virus and liver disease: global transcriptional profiling and identification of potential markers. Hepatology 38 (2003) 1458-1467
166. Kim S., Han S., Azam T., Yoon D., and Dinarello C. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity 22 (2005) 131-142
167. Netea M., Azam T., Ferwerda G., et al. IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism. Proc Natl Acad Sci USA 102 (2005) 16309-16314
168. Wang E., Panelli M., Zavaglia K., et al. Melanoma-restricted genes. J Transl Med 2 (2004) 34
169. Marincola F. A balanced review of the status of T cell-based therapy against cancer. J Transl Med 3 (2005) 16
170. Monsurro V., Wang E., Panelli M., et al. Active-specific immunization against melanoma: is the problem at the receiving end?. Semin Cancer Biol 13 (2003) 473-480
171. Panelli M., Riker A., Kammula U., et al. Expansion of tumor T-cell pairs from fine needle aspirates of melanoma metastases. J Immunol 164 (2000) 495-504
172. Kammula U., Marincola F., and Rosenberg S. Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination. J Natl Cancer Inst 92 (2000) 1336-1344
173. Richwald G. Imiquimod. Drugs Today 35 (2003) 497-511
174. Urosevic M., Maier T., Benninghoff B., Slade H., Burg G., and Dummer R. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol 139 (2003) 1325-1332
175. Dahl M. Imiquimod: a cytokine inducer. J Am Acad Dermatol 47 4 suppl (2002) S205-S208
176. Iwasaki A., and Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 5 (2004) 987-995
177. Hemmi H., Kaisho T., Takeuchi O., et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3 (2002) 196-200
178. Urosevic M., Dummer R., Conrad C., et al. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst 97 (2005) 1143-1153
179. Panelli M., Stashower M., Slade H., et al. Sequential gene profiling of basal cell carcinomas treated with Imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biol 8 (2007) R8